Whitehawk Therapeutics (WHWK) EBIAT: 2018-2025
Historic EBIAT for Whitehawk Therapeutics (WHWK) over the last 7 years, with Sep 2025 value amounting to -$17.7 million.
- Whitehawk Therapeutics' EBIAT fell 41.45% to -$17.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 74.67%. This contributed to the annual value of -$63.7 million for FY2024, which is 3.14% up from last year.
- According to the latest figures from Q3 2025, Whitehawk Therapeutics' EBIAT is -$17.7 million, which was up 66.27% from -$52.6 million recorded in Q2 2025.
- In the past 5 years, Whitehawk Therapeutics' EBIAT registered a high of $73.0 million during Q1 2025, and its lowest value of -$87.1 million during Q3 2021.
- For the 3-year period, Whitehawk Therapeutics' EBIAT averaged around -$11.5 million, with its median value being -$16.3 million (2023).
- Per our database at Business Quant, Whitehawk Therapeutics' EBIAT crashed by 2,911.34% in 2021 and then soared by 498.99% in 2025.
- Over the past 5 years, Whitehawk Therapeutics' EBIAT (Quarterly) stood at -$16.0 million in 2021, then climbed by 13.04% to -$13.9 million in 2022, then declined by 16.91% to -$16.3 million in 2023, then declined by 12.40% to -$18.3 million in 2024, then slumped by 41.45% to -$17.7 million in 2025.
- Its EBIAT was -$17.7 million in Q3 2025, compared to -$52.6 million in Q2 2025 and $73.0 million in Q1 2025.